What's New


 

 


Our mission is to improve and extend the lives of patients with cancer by discovering and developing novel products based on our CombiPlex® technology.



 
CombiPlex®, Celator’s proprietary technology platform, introduces for the first time, the ability to collect in vitro drug combination informatics and apply those findings directly to the development of new clinically viable drug products.
This unique approach reflects several advantages:

1. The ability to identify drug combinations that exhibit ratio-dependent anti-tumor activity in vitro;
2. The opportunity to “lock” the synergistic ratio of drug agents in an effective drug delivery vehicle; and,
3. The ability to deliver and maintain the drug combination in vivo with the synergistic drug ratio consistently maintained.
 
 
 
Improving and Extending the Lives of Patients with Cancer

 


© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.